Halvard Bonig

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7223150/halvard-bonig-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181 3,964 36 55 h-index g-index citations papers 4,839 5.31 205 4.5 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
181	Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment 2022 , 31-36		
180	Management of Chronic Graft-vsHost Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan <i>Frontiers in Pediatrics</i> , 2022 , 10, 808103	3.4	1
179	Superior physical and mental health of healthy volunteers before and fivelyears after mobilized stem cell donation <i>Journal of Translational Medicine</i> , 2022 , 20, 121	8.5	
178	Severe impairment of T-cell responses to BNT162b2 immunization in multiple myeloma patients. <i>Blood</i> , 2021 ,	2.2	3
177	Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 348	8 1.2 48	1
176	Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia <i>Frontiers in Pediatrics</i> , 2021 , 9, 784377	3.4	
175	Generation and validation of a formula to calculate hemoglobin loss on a cohort of healthy adults subjected to controlled blood loss. <i>Journal of Translational Medicine</i> , 2021 , 19, 116	8.5	O
174	CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. <i>Gene Therapy</i> , 2021 , 28, 560-571	4	23
173	Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. <i>Journal of Translational Medicine</i> , 2021 , 19, 145	8.5	3
172	Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations. Journal of Translational Medicine, 2021 , 19, 190	8.5	1
171	Depletion of CD45RA T cells: Advantages and disadvantages of different purification methods. Journal of Immunological Methods, 2021 , 492, 112960	2.5	O
170	PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. <i>Oncogenesis</i> , 2021 , 10, 42	6.6	0
169	Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing. <i>Blood</i> , 2021 , 138, 814-817	2.2	O
168	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates NaWe and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 2924-2943	24.4	5
167	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021 , 138, 1830-1842	2.2	9
166	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in	3.4	5
165	Pediatrics, 2021, 9, 705179 ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90	4.4	1

164	CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust. <i>Clinical Hematology International</i> , 2021 , 3, 103-107	1.8	1
163	Special Clinical Scenarios: Hyperleukocytosis. <i>Hematologic Malignancies</i> , 2021 , 267-273	Ο	2
162	Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. <i>Leukemia</i> , 2021 ,	10.7	1
161	Results of a multicenter phase I/II trial of TCRIand CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	6
160	Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis. <i>Haematologica</i> , 2020 , 105, e328-e332	6.6	11
159	Introduction of principles of blood management to healthy donor bone marrow harvesting. <i>Vox Sanguinis</i> , 2020 , 115, 802-812	3.1	2
158	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1126-1136	4.4	8
157	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020 , 34, 1907-1923	10.7	10
156	Reducing the red blood cell transfusion threshold from 8D g/dl to 7D g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome. <i>Vox Sanguinis</i> , 2020 , 115, 570-578	3.1	4
155	Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity. <i>Cells</i> , 2020 , 9,	7.9	7
154	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. <i>Blood</i> , 2020 , 136, 26-26	2.2	5
153	Development and Exploitation of a Fully Human and Modular Organotypic Bone Marrow Niche Model to Study the Role of Stroma-Produced Factors in Human MDS. <i>Blood</i> , 2020 , 136, 23-23	2.2	2
152	Integrin B mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020 , 136, 210-2	23 .2	14
151	Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors. <i>Journal of Translational Medicine</i> , 2020 , 18, 487	8.5	
150	Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1338-1350	8.9	4
149	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020 , 105, 297-316	6.6	122
148	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020 , 11, 581468	8.4	6
147	Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. <i>Frontiers in Immunology</i> , 2020 , 11, 2028	8.4	19

146	Mesenchymal stromal cells for osteonecrosis. Journal of Translational Medicine, 2020, 18, 399	8.5	5
145	Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients. <i>Journal of Clinical Apheresis</i> , 2020 , 35, 398-405	3.2	4
144	The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis. <i>Scientific Reports</i> , 2020 , 10, 21438	4.9	2
143	Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. <i>Journal of Translational Medicine</i> , 2020 , 18, 177	8.5	17
142	Hematopoietic-Extrinsic Cues Dictate Circadian Redistribution of Mature and Immature Hematopoietic Cells in Blood and Spleen. <i>Cells</i> , 2019 , 8,	7.9	7
141	Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 1218	8.4	9
140	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. <i>Cell Reports</i> , 2019 , 27, 2022-2028.e3	10.6	21
139	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1281-1292	4.7	17
138	Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. <i>Transfusion Medicine and Hemotherapy</i> , 2019 , 46, 27-34	4.2	46
137	Modest and nonessential roles of the endocannabinoid system in immature hematopoiesis of mice. <i>Experimental Hematology</i> , 2019 , 78, 35-45	3.1	
136	Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. Journal of Clinical Investigation, 2019 , 129, 2745-2759	15.9	20
135	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. <i>Blood</i> , 2019 , 134, 2059-2059	2.2	28
134	Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors. <i>Blood</i> , 2019 , 134, 592-592	2.2	
133	Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy. <i>Blood</i> , 2019 , 134, 2623-2623	2.2	
132	Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice. Cells, 2019, 9,	7.9	4
131	Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. <i>Oncogene</i> , 2019 , 38, 4788-4803	9.2	21
130	Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients. <i>Cells</i> , 2019 , 8,	7.9	22
129	Mobilized peripheral blood stem cell apheresis via Hickman catheter in pediatric patients. <i>Transfusion</i> , 2019 , 59, 1061-1068	2.9	2

128	FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation. <i>PLoS ONE</i> , 2019 , 14, e0210515	3.7	4
127	Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. <i>Molecular Therapy</i> , 2018 , 26, 1137-1153	11.7	33
126	Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. <i>Cytotherapy</i> , 2018 , 20, 532-542	4.8	17
125	Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). <i>Bone Marrow Transplantation</i> , 2018 , 53, 852-862	4.4	59
124	CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , 2018 , 32, 1168-1179	10.7	97
123	Autologous cell-based therapy for treatment of large bone defects: from bench to bedside. European Journal of Trauma and Emergency Surgery, 2018 , 44, 649-665	2.3	33
122	Phase II study of haploidentical stem cell transplantation using ex vivo photodepletion of donor lymphocyte infusions to eliminate anti-host reactivity results in low relapse rates and high survival rates: Final 2 year follow-up. <i>Cytotherapy</i> , 2018 , 20, S10-S11	4.8	2
121	Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34 progenitor cells. <i>Haematologica</i> , 2018 , 103, 18-29	6.6	8
120	Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 25-38	7.4	54
119	Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy. <i>Blood</i> , 2018 , 132, 3476-3476	2.2	3
118	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. <i>Blood</i> , 2018 , 132, 604-604	2.2	1
117	Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients. <i>Blood</i> , 2018 , 132, 603-603	2.2	1
116	FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells. <i>Blood</i> , 2018 , 132, 903-903	2.2	2
115	Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. <i>Blood</i> , 2018 , 132, 120-120	2.2	1
114	The osteo-inductive activity of bone-marrow-derived mononuclear cells resides within the CD14+ population and is independent of the CD34+ population. <i>European Cells and Materials</i> , 2018 , 35, 165-17	74.3	16
113	Mesenchymale Stromazellen auf dem Weg zur klinischen Anwendung: Update 2018. Transfusionsmedizin Immunhinatologie Hinotherapie Transplantationsimmunologie Zelltherapie, 2018 , 8, 148-159	0.1	O
112	Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. <i>Blood</i> , 2018 , 131, 1022-1031	2.2	161
111	A Proof of the Low Speed Centrifugation Concept in Rodents: New Perspectives for In Vivo Research. <i>Tissue Engineering - Part C: Methods</i> , 2018 , 24, 659-670	2.9	15

110	Risks of leukapheresis and how to manage them-A non-systematic review. <i>Transfusion and Apheresis Science</i> , 2018 , 57, 628-634	2.4	8
109	Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. <i>Cytotherapy</i> , 2018 , 20, 839-850	4.8	6
108	Generation and flow cytometric quality control of clinical-scale TCRICD19-depleted grafts. <i>Cytometry Part B - Clinical Cytometry</i> , 2017 , 92, 126-135	3.4	7
107	Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. <i>Journal of Translational Medicine</i> , 2017 , 15, 2	8.5	33
106	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017 , 31, 549-562.e11	24.3	59
105	Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. <i>Blood</i> , 2017 , 129, 2939-2949	2.2	25
104	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , 2017 , 129, 598-608	2.2	16
103	The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1545-1550	12.3	36
102	A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization. <i>PLoS ONE</i> , 2017 , 12, e0179986	3.7	4
101	Effects of CD49d-targeted antisense-oligonucleotide on [4] integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. <i>PLoS ONE</i> , 2017 , 12, e0187684	1 ^{3.7}	6
100	Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC. <i>Journal of Translational Medicine</i> , 2017 , 15, 174	8.5	5
99	Defective IL-23/IL-17 Axis Protects p47phox-/- Mice from Colon Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 44	8.4	10
98	Promises and Challenges in Hematopoietic Stem Cell Gene Therapy. Human Gene Therapy, 2017 , 28, 782	2- 4 7. 9 9	4
97	Hematopoietic transcription factors and differential cofactor binding regulate isoform expression. <i>Oncotarget</i> , 2017 , 8, 71685-71698	3.3	3
96	Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. <i>Transfusion</i> , 2016 , 56, 2336-45	2.9	9
95	Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. Haematologica, 2016 , 101, e153-6	6.6	31
94	In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy. <i>Journal of Translational Medicine</i> , 2016 , 14, 264	8.5	6
93	Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. <i>Transfusion</i> , 2016 , 56, 3055-3064	2.9	20

(2015-2016)

8.5	17
3.1	14
66 ^{9.5}	23
20.5	67
5.1	6
2.2	8
2.2	1
2.2	11
3.3	15
2.2	
6	15
3.3	5
8.5	22
4.8	2
6.6	52
3.9	37
2.2	8
4.8	15
	6 3.3 8.5 4.8 6.6 3.9

74	Discovery and characterization of an endogenous CXCR4 antagonist. Cell Reports, 2015, 11, 737-47	10.6	56
73	CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. <i>Stem Cells and Development</i> , 2015 , 24, 714-23	4.4	14
72	Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3957-68	12.9	18
71	Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. <i>Cytotherapy</i> , 2015 , 17, 1396-405	4.8	23
70	Functional consequences of perturbed CXCL12 signal processing: analyses of immature hematopoiesis in GRK6-deficient mice. <i>Stem Cells and Development</i> , 2015 , 24, 737-46	4.4	8
69	Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. <i>Molecular Therapy</i> , 2015 , 23, 330-8	11.7	187
68	Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. <i>Cytotherapy</i> , 2015 , 17, 128-39	4.8	91
67	Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?. <i>Transfusion</i> , 2015 , 55, 430-9	2.9	24
66	Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. <i>Vox Sanguinis</i> , 2015 , 109, 387-93	3.1	16
65	In vitro migration and proliferation ("wound healing") potential of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells. <i>Journal of Translational Medicine</i> , 2015, 13, 315	8.5	35
64	Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. <i>Transfusion</i> , 2015 , 55, 1275-82	2.9	26
63	Impact of Charged Particle Exposure on Homologous DNA Double-Strand Break Repair in Human Blood-Derived Cells. <i>Frontiers in Oncology</i> , 2015 , 5, 250	5.3	13
62	Variant rs1801157 in the 3PUTR of SDF-1Idoes not explain variability of healthy-donor G-CSF responsiveness. <i>PLoS ONE</i> , 2015 , 10, e0121859	3.7	10
61	Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro. <i>BioMed Research International</i> , 2015 , 2015, 762407	3	23
60	RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. <i>Blood</i> , 2015 , 125, 3570-9	2.2	68
59	Concise Review: CXCR4/CXCL12 Signaling in Immature HematopoiesisLessons From Pharmacological and Genetic Models. <i>Stem Cells</i> , 2015 , 33, 2391-9	5.8	60
58	Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. <i>Cytotherapy</i> , 2015 , 17, 1465-71	4.8	31
57	Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10. <i>Blood</i> , 2015 , 126, 2525-2525	2.2	1

(2013-2015)

56	Donor Lymphocytes Depleted of Alloreactive 1-Cells (ATR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen. <i>Blood</i> , 2015 , 126, 4391-4391	2.2	3
55	Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF. <i>Blood</i> , 2015 , 126, 511-511	2.2	2
54	Clinical-scale isolation of Pminimally manipulated Pcytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. <i>Cytotherapy</i> , 2014 , 16, 1245-56	4.8	44
53	Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34(+) cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers. <i>Cytotherapy</i> , 2014 , 16, 1558-1574	4.8	7
52	PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. <i>Nature Communications</i> , 2014 , 5, 3995	17.4	46
51	Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. <i>Transfusion</i> , 2014 , 54, 1622-9	2.9	33
50	Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. <i>Blood</i> , 2014 , 124, 240-50	2.2	38
49	Role of integrin alpha4 in drug resistance of leukemia. Frontiers in Oncology, 2014, 4, 99	5.3	59
48	In reply. <i>Transfusion</i> , 2014 , 54, 2585-6	2.9	
47	The challenges of autologous cell therapy: systemic anti-thrombotic therapies interfering with serum coagulation may disable autologous serum-containing cell products for therapeutical use. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 644-50	3.3	3
46	Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. <i>Cytotherapy</i> , 2014 , 16, 835-44	4.8	16
45	Pediatric apheresis with a novel apheresis device with electronic interface control. <i>Transfusion</i> , 2013 , 53, 761-5	2.9	30
44	Epigenetic modifications and chromosome conformations of the beta globin locus throughout development. <i>Stem Cell Reviews and Reports</i> , 2013 , 9, 397-407	6.4	15
43	Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. <i>Haematologica</i> , 2013 , 98, 1609-	16.6 16	35
42	Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1141-3	4.4	24
41	Leucodepletion for hyperleucocytosisfirst report on a novel technology featuring electronic interphase management. <i>Vox Sanguinis</i> , 2013 , 105, 47-53	3.1	10
40	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. <i>Blood</i> , 2013 , 121, 1814-8	2.2	82
39	Granulocyte collections: comparison of two apheresis systems. <i>Transfusion</i> , 2013 , 53, 3262-8	2.9	16

38	Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. <i>PLoS ONE</i> , 2013 , 8, e75184	3.7	140
37	Allogeneic donor peripheral blood "stem cell" apheresis: prospective comparison of two apheresis systems. <i>Transfusion</i> , 2012 , 52, 1137-45	2.9	65
36	Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. <i>Methods in Molecular Biology</i> , 2012 , 904, 1-14	1.4	41
35	Intracoronary bone marrow cell application for terminal heart failure in children. <i>Cardiology in the Young</i> , 2012 , 22, 558-63	1	40
34	The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy. <i>Blood</i> , 2012 , 120, 1500-1500	2.2	2
33	Rapid and Potent Mobilization of Murine Hematopoietic Stem and Progenitor Cells by the Novel CXCR4 Antagonist POL5551. <i>Blood</i> , 2012 , 120, 4100-4100	2.2	
32	Mesenchymal stromal cells derived from CD271(+) bone marrow mononuclear cells exert potent allosuppressive properties. <i>Cytotherapy</i> , 2011 , 13, 1193-204	4.8	19
31	Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BDIstem cell enumeration kit. <i>Cytotherapy</i> , 2011 , 13, 449-58	4.8	36
30	Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 331-7	4.2	38
29	Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: an overview. <i>Stem Cells International</i> , 2011 , 2011, 791604	5	20
28	Automatic interface-controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device. <i>Transfusion</i> , 2011 , 51, 1321-30	2.9	62
27	Asystole during stem cell apheresis in a young healthy female volunteer donor. <i>Transfusion</i> , 2011 , 51, 1594-5	2.9	2
26	Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics. <i>Molecular Diagnosis and Therapy</i> , 2011 , 15, 13-9	4.5	4
25	Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. <i>Circulation Research</i> , 2011 , 109, 1219-29	15.7	90
24	GRK6 Ablation Is Associated with Surprisingly Modest Effects on Immature Hematopoiesis. <i>Blood</i> , 2011 , 118, 2381-2381	2.2	
23	Vagrant stem cells draft their gene companions. <i>Cell Stem Cell</i> , 2010 , 7, 547-8	18	
22	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. <i>Blood</i> , 2010 , 116, 869-869	2.2	1
21	Blockade of alpha6-integrin reveals diversity in homing patterns among human, baboon, and murine cells. <i>Stem Cells and Development</i> , 2009 , 18, 839-44	4.4	10

(2001-2009)

20	Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. <i>Experimental Hematology</i> , 2009 , 37, 402-15.e	1 3.1	44
19	Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. <i>Stem Cells</i> , 2009 , 27, 836-7	5.8	51
18	On the adaptation of endosteal stem cell niche function in response to stress. <i>Blood</i> , 2009 , 114, 3773-8	322.2	35
17	Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL <i>Blood</i> , 2009 , 114, 3089-3089	2.2	1
16	Blood types of current embryonic stem cell lines are not conducive to culturing "universal-donor" red blood cells. <i>Transfusion</i> , 2008 , 48, 1039-40	2.9	10
15	Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. <i>Blood</i> , 2008 , 111, 3439-41	2.2	143
14	Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors. <i>Blood</i> , 2008 , 112, 209-210	2.2	4
13	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008 , 112, 858-858	2.2	4
12	Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. <i>Experimental Hematology</i> , 2007 , 35, 326-34	3.1	46
11	Hematopoietic Stem/Progenitor Cells (HSPC) Mobilization Parameters in Patients Chronically Treated with the CD49d Blocking Antibody Natalizumab <i>Blood</i> , 2007 , 110, 177-177	2.2	1
10	Insights into the Biology of Mobilized Cells through Innovative Treatment Schedules of the CXCR4 Antagonist AMD3100 <i>Blood</i> , 2007 , 110, 2229-2229	2.2	1
9	Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. <i>Blood</i> , 2006 , 107, 79-86	2.2	78
8	The p67 laminin receptor identifies human erythroid progenitor and precursor cells and is functionally important for their bone marrow lodgment. <i>Blood</i> , 2006 , 108, 1230-3	2.2	11
7	Long-term functional impairment of hemopoietic progenitor cells engineered to express the S1 catalytic subunit of pertussis toxin. <i>Experimental Hematology</i> , 2005 , 33, 689-98	3.1	5
6	PTX-sensitive signals in bone marrow homing of fetal and adult hematopoietic progenitor cells. <i>Blood</i> , 2004 , 104, 2299-306	2.2	38
5	Gi Protein Signals Are Required for BM Homing of Hemopoietic Progenitor Cells, and Cooperate with Alpha4-Intergrin and Endothelial Selectins <i>Blood</i> , 2004 , 104, 2183-2183	2.2	
4	The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. <i>Blood</i> , 2003 , 101, 4739-47	2.2	92
3	Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphomaa rationale for tailored supportive care. <i>Supportive Care in Cancer</i> , 2001 , 9, 514-21	3.9	24

Release of the soluble interleukin-6 receptor from human T-cells. *Immunological Investigations*, **1998**, 27, 47-55

2.9 4

Genomic Analyses of SLAMF7 CAR-T Cells Manufactured by Sleeping Beauty Transposon Gene Transfer for Immunotherapy of Multiple Myeloma

5